Concord Biotech Limited (NSEI: CONCORDBIO)
Health Care · Pharmaceuticals · IN
Rs1,451.30
+6.32% today · -11.2% 1Y
Concord Biotech Limited (NSEI: CONCORDBIO) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.59B and employs 1,624 people.
Over the last twelve months the share price has lost 11.2%, trading between 987.00 and 1.80K.
Tweenvest scores Concord Biotech Limited across four factors: quality 72/100, value 43/100, growth 65/100, dividend 44/100. Its strongest factor is quality.
CONCORDBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.59B
- Revenue (TTM)
- $117.23M
- P/E
- 55.32
- EPS
- 26.24
- Dividend yield
- 0.52%
- Beta (5Y)
- 0.35
- 52-week high
- Rs1,801.90
- 52-week low
- Rs987.00
- Avg volume (3M)
- —
- Shares outstanding
- 104.62M
- Employees
- 1,624
- Next earnings
- —
About Concord Biotech Limited
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
- ISIN
- INE338H01029
- Founded
- 1984
- Listed since
- Aug 18, 2023
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,235.16 | +0.12% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.15 | +0.00% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.34 | -0.07% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.70 | -0.03% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.52 | -0.99% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.51 | -0.21% |
Figures last refreshed Aug 18, 2026.